Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
August 06, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
July 07, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent

SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
June 18, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak

SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
June 16, 2015 11:40 ET | Source: SteadyMed Therapeutics

SteadyMed to Present at the JMP Securities Life Sciences Conference

SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...